LETTER TO JMG

Genotype-phenotype correlations for cataracts in neurofibromatosis 2

M E Baser, L Kuramoto, H Joe, J M Friedman, A J Wallace, R T Ramsden, D G R Evans

N eurofibromatosis 2 (NF2) is an autosomal dominant disease that is caused by inactivating mutations of the NF2 tumour suppressor gene. Multiple central and peripheral nervous system tumours and ocular abnormalities are common in NF2; bilateral vestibular schwannomas are pathognomonic for the disease. Genotype-phenotype correlations are well established for NF2-associated tumours. In general, constitutional nonsense or frameshift NF2 mutations are associated with severe NF2 (that is, earlier onset of symptoms and more tumours), splice site mutations with variable disease severity, and missense mutations with mild disease.

Genotype-phenotype correlations have not been reported for the non-tumour manifestations of NF2. The most common of these manifestations is presenile cataracts, which occur in about 60–80% of people with NF2. In animal models, lens fibre cells that are more differentiated express less NF2 protein than the epithelial regions of the lens, suggesting that the NF2 protein may play a role in lens epithelial cell migration or elongation. The purpose of this study was to determine if there were genotype-phenotype correlations for cataracts in NF2.

PATIENTS AND METHODS

The study was based on the United Kingdom NF2 registry in the Department of Medical Genetics, St Mary’s Hospital, Manchester. NF2 patients are ascertained by contacting neurosurgeons, otolaryngologists, neurologists, paediatricians, dermatologists, and geneticists throughout the United Kingdom, augmented in the North West Region by the Regional Cancer Registry. The study was subject to continuing ethics committee evaluation and patients consented to participation. Patients were screened for constitutional NF2 mutations using single strand conformational polymorphism analysis (SSCP) as previously described, and examined for cataracts using slitlamp biomicroscopy at the time of diagnosis of NF2. For this study, cataracts were defined as present or absent (that is, posterior subcapsular cataracts and cortical cataracts were aggregated). There were 255 people from 190 families (159 people with new mutations and 96 inherited cases; 132 females and 123 males) (table 1).

For univariate analyses, Fisher’s exact test was used for binary variables and the two-tailed t test was used for continuous variables. A multivariate probit model with an exchangeable correlation structure within families was used with various sets of covariates to account for possible familial dependence. From a regression coefficient β, an approximate relative risk (RR = exp(2β)) and confidence interval (CI) for presence of cataracts can be calculated. In the probit model, the reference group in comparisons between people with different types of NF2 mutations was people who had constitutional nonsense or frameshift NF2 mutations.

There is a potential bias towards a lower age at onset of symptoms or age at diagnosis in inherited cases owing to the family history of the disease. In the study group as a whole, there were no significant differences in these ages between people with new mutations and inherited cases for any type of NF2 mutation. Also, using a probit model, the RR of cataracts was not significantly associated with age at diagnosis (see below). Therefore, for all mutation categories except unfound mutations, we combined people with new mutations and inherited cases. In the large group of people with unfound mutations, we retained the division between those with new mutations and inherited disease because people with new unfound mutations may be somatic mosaics. We used age at onset of symptoms to categorise people with new unfound mutations by disease severity (severe disease, onset of symptoms at ages <20 years; mild disease, onset of symptoms at ages ≥20 years).

RESULTS

As expected, the mean age at onset of symptoms and age at diagnosis were higher in people with non-truncating mutations and in somatic mosaics than in people with classical NF2 and nonsense or frameshift mutations (table 1). The overall prevalence of cataracts was 33%, but the prevalence of cataracts was significantly lower in somatic mosaics and in people with new unfound mutations and onset of symptoms at ages ≥20 years than in people with classical NF2 and nonsense or frameshift mutations. In people with cataracts, 29% were diagnosed with cataracts at ages <10 years, and 47% at ages <20 years (median (SE) 2 years). Seventy percent were diagnosed with cataracts before their first non-ocular sign or symptom.

In the multivariate probit model summarised in table 2, the RR of cataracts did not significantly increase with increasing age at diagnosis, after accounting for the type of constitutional NF2 mutation. This was also the case in the other probit models (data not shown). This is probably due to the
relatively young study population (mean age at diagnosis 28 years (SE 1); only 5% diagnosed at ages ≥55 years and 2% at ages ≥60 years), since the prevalence of posterior subcapsular and cortical cataracts in people aged <55 years in the general population is very low. The RR of cataracts was less than 1 in all mutation groups as compared to people with classical NF2 and nonsense or frameshift mutations. The RR was significantly lower than 1 in somatic mosaics (RR = 0.20, 95% CI = 0.10 to 0.40), in people with large deletions (RR = 0.39, 95% CI = 0.16 to 0.98), and in people with new unfound mutations and onset of symptoms at ages ≥20 years (RR = 0.09, 95% CI = 0.03 to 0.28). The RR of cataracts in people with missense mutations was lower than 1 but not statistically significantly so (RR = 0.38, 95% CI = 0.14 to 1.08).

**DISCUSSION**

The low RR of cataracts in somatic mosaics, in people with large deletions, and in people with new unfound mutations and older onset of symptoms is consistent with the generally mild disease in NF2 patients with each of these types of mutations or conditions. The low RR of cataracts in people with new unfound mutations and older onset of symptoms could be due to several types of mutations or conditions that are unlikely to be identified by SSCP, and that are known to be associated or likely to be associated with mild NF2. These mutations or conditions are somatic mosaicism; large deletions, insertions, or other rearrangements; mutations in the 3 or 5 untranslated regions, the promoter region, or untranscribed transcriptional control elements; intronic mutations that are not covered by conventional SSCP primers; or other epigenetic events causing loss of NF2 expression, such as methylation.

Somatic mosaicism and large deletions are the most likely of these possibilities. In the present study, 17 (18%) of the 92 patients with new mutations and identified constitutional NF2 mutations were somatic mosaics. The estimated prevalence of somatic mosaicism in NF2 patients with new mutations is 25–30%. Some of the NF2 patients with new unfound mutations and mild disease may be somatic mosaics in whom conventional DNA sequencing of lymphocyte DNA PCR product has failed to identify a difference from the normal sequence because the mutant allele is present at too low a level to be detected. Constitutional NF2 large deletions

**Table 1** Characteristics of study population by type of NF2 mutation

<table>
<thead>
<tr>
<th>No. of people/families</th>
<th>Classical</th>
<th>Somatic mosaic</th>
<th>Splice site</th>
<th>Missense</th>
<th>Large deletion</th>
<th>Inherited cases</th>
<th>People with new mutations (age of onset (y))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onset of symptoms†</td>
<td>16 (9)</td>
<td>32 (12)</td>
<td>23 (12)</td>
<td>30 (14)</td>
<td>21 (9)</td>
<td>25 (16)</td>
<td>12 (6)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>21 (12)</td>
<td>38 (12)</td>
<td>27 (15)</td>
<td>38 (21)</td>
<td>23 (9)</td>
<td>29 (17)</td>
<td>22 (12)</td>
</tr>
<tr>
<td>Current</td>
<td>27 (12)</td>
<td>44 (12)</td>
<td>32 (16)</td>
<td>45 (21)</td>
<td>30 (11)</td>
<td>35 (20)</td>
<td>29 (12)</td>
</tr>
<tr>
<td>Infratemporal mosaics</td>
<td>56</td>
<td>59</td>
<td>34</td>
<td>27</td>
<td>52</td>
<td>14</td>
<td>70</td>
</tr>
<tr>
<td>Cataracts (%)</td>
<td>45</td>
<td>18</td>
<td>38</td>
<td>27</td>
<td>28</td>
<td>36</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

†Excludes 15 inherited cases who were asymptomatic at the time of diagnosis of NF2.

Comparisons to people with classical NF2 and nonsense or frameshift mutations (p values are computed based on an assumption of independence, which is violated to a slight degree owing to families with multiple affected relatives): Somatic mosaics: age at onset, age at diagnosis, current age, p < 0.001; cataracts, p = 0.053.

Splice site mutations: age at onset, p = 0.001; age at diagnosis, p = 0.023; current age, p = 0.043; intracranial meningiomas, p = 0.024.

Missense mutations: age at onset, p = 0.003; age at diagnosis, p = 0.006; current age, p < 0.001; intracranial meningiomas, p = 0.049.

Large deletions: age at onset, p = 0.032.

Unfound mutations:

Inherited cases: intracranial meningiomas, p = 0.007.

People with new mutations and age at onset 20 years: cataracts, p = 0.053.

People with new mutations and age at diagnosis 20 years: cataracts, p = 0.001.

Inherited cases: intracranial meningiomas, p = 0.007.

Unfound mutations: intracranial meningiomas, p = 0.007.

**Table 2** Multivariate probit model for cataracts

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Estimated prevalence of cataracts from model (%)</th>
<th>Parameter estimate (SE)</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (per year)</td>
<td>0.15 (0.58)</td>
<td>1.00</td>
<td>0.98</td>
<td>1.02</td>
</tr>
<tr>
<td>Exchangeable dependence (familial correlation)</td>
<td>0.11 (0.15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of NF2 mutation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsense or frameshift</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Classical NF2</td>
<td>45</td>
<td>Reference group</td>
<td></td>
<td>Reference group</td>
</tr>
<tr>
<td>Somatic mosaic</td>
<td>17</td>
<td>-0.82 (0.18)</td>
<td>0.20</td>
<td>0.10 to 0.40</td>
</tr>
<tr>
<td>Splice site</td>
<td>39</td>
<td>-0.17 (0.19)</td>
<td>0.71</td>
<td>0.34 to 1.50</td>
</tr>
<tr>
<td>Missense</td>
<td>28</td>
<td>-0.48 (0.26)</td>
<td>0.38</td>
<td>0.14 to 1.08</td>
</tr>
<tr>
<td>Large deletion</td>
<td>28</td>
<td>-0.47 (0.23)</td>
<td>0.39</td>
<td>0.16 to 0.98</td>
</tr>
<tr>
<td>Unfound</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>People with new mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at onset ≥ 20 years</td>
<td>39</td>
<td>-0.15 (0.15)</td>
<td>0.74</td>
<td>0.40 to 1.36</td>
</tr>
<tr>
<td>Age at onset ≥ 20 years</td>
<td>9</td>
<td>-1.20 (0.28)</td>
<td>0.09</td>
<td>0.03 to 0.28</td>
</tr>
<tr>
<td>Inherited cases</td>
<td>36</td>
<td>-0.23 (0.34)</td>
<td>0.63</td>
<td>0.16 to 2.45</td>
</tr>
</tbody>
</table>

RR = relative risk, CI = confidence interval, SE = standard error.
have been found in 21% of NF2 families using microarray comparative genomic hybridisation, and in 32% of NF2 families using multiple mutation screening methods.

The intrafamilial correlation for cataracts was weak (and statistically insignificant) in all multivariate probit models that were tried, although there were relatively few families with multiple affected relatives. Several other clinical features of NF2 (age at onset of symptoms, age at diagnosis, and number of intracranial meningiomas) have strong familial correlations. The prevalence of cataracts in the present study was lower than in other studies, probably because the population-based United Kingdom NF2 registry is less heavily weighted towards NF2 patients with severe disease than studies of patients from tertiary referral clinics, and because some cataract examinations were done by medical specialists other than ophthalmologists. Non-ophthalmologists may miss faint cataracts, but in such cases it is unlikely that faint cataracts are missed more frequently in people with mild NF2 than in those with severe NF2 (that is, it will not bias genotype-phenotype correlations). In a previous study based on the UK NF2 registry, all patients were examined using slitlamp biomicroscopy by a non-ophthalmologist, and the prevalence of cataracts was similar in mild cases (35%) and in severe cases (40%).

The genotype-phenotype correlations for cataracts in the present study extend the correlations that have been reported for the tumour manifestations of NF2. The high prevalence of cataracts in young NF2 patients, and their frequent occurrence before the tumour manifestations of NF2, underline the importance of non-8th nerve signs and symptoms of NF2 in children and adolescents as a useful aid to diagnosis in this age group.

ACKNOWLEDGEMENTS

Supported in part by the FBT Foundation and US Army grant USARMC NFP90038.

Authors’ affiliations
M E Baser, Los Angeles, CA, USA
L Kuramoto, H Joe, Department of Biostatistics, University of British Columbia, Vancouver, BC, Canada
J M Friedman, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
A J Wallace, D G R Evans, Department of Medical Genetics, St Mary’s Hospital, Manchester, UK
R T Ramsden, Department of Otolaryngology, Manchester Royal Infirmary, Manchester, UK

Correspondence to: Dr M E Baser, 2257 Fox Hills Drive, Los Angeles, CA 90064, USA; michael.baser@sbcglobal.net

REFERENCES


Genotype-phenotype correlations for cataracts in neurofibromatosis 2

M E Baser, L Kuramoto, H Joe, J M Friedman, A J Wallace, R T Ramsden and D G R Evans

doi: 10.1136/jmg.40.10.758

Updated information and services can be found at:
http://jmg.bmj.com/content/40/10/758

These include:

Supplementary Material
Supplementary material can be found at:
http://jmg.bmj.com/content/suppl/2004/01/05/40.10.758.DC1
http://jmg.bmj.com/content/suppl/2004/01/05/40.10.758.DC2

References
This article cites 15 articles, 5 of which you can access for free at:
http://jmg.bmj.com/content/40/10/758#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/41/3/240.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections
- Eye Diseases (298)
- Ethics (220)
- Molecular genetics (1254)
- Neuromuscular disease (257)
- Neurooncology (78)
- Peripheral nerve disease (97)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Loci for primary ciliary dyskinesia map to chromosome 16p12.1-12.2 and 15q13.1-15.1 in Faroe Islands and Israeli Druze genetic isolates


Primary ciliary dyskinesia (PCD; Immotile cilia syndrome; OMIM 242650) is an autosomal recessive disorder resulting from dysmotility of cilia and sperm flagella. Cilia and flagella function either to create circulation of fluid over a stationary cell surface or to propel a cell through fluid. These related structures are highly complex organelles composed of over 200 different polypeptides. The core or axoneme of cilia and flagella comprises a bundle of microtubules and many associated proteins. The microtubules are formed from α and β tubulin protofilaments and are arranged in a well recognised ‘9+2’ pattern: nine peripheral microtubule doublets in a ring connected around a central pair of microtubules by radial spoke proteins. The peripheral microtubules have dynein motor proteins attached and are connected with each other by nexin links.

In human beings, ciliated epithelium can be found lining the respiratory tract, including the sinuses and middle ear, the brain ependyma, the female oviduct, and the male vas deferens. Cilia in the respiratory tract play an important part in airway clearance of respiratory secretions. In primary ciliary dyskinesia, impaired mucociliary clearance causes recurrent respiratory tract infections including chronic otitis media, rhinitis, and sinusitis, often leading to permanent lung damage (bronchiectasis). Patients are also often subfertile due to sperm tail immotility and immotile oviduct cilia. About half of the patients have defects of laterality, usually complete mirror-image reversal of the left-right axis (situs inversus) and this association is known as Kartagener syndrome. Primary ciliary dyskinesia has an estimated incidence of 1 in 20 000 live births.

Primary ciliary dyskinesia has an incidence of 1 in 20 000 with enrichment in certain populations. Diagnosis is made on brushings or biopsy of nasal epithelium by demonstration of abnormal ciliary beating, and by demonstration of ultrastructural defects of cilia by electron microscopy.

Primary ciliary dyskinesia is a chronic condition with symptoms present from birth but there is significant variation both in clinical severity and the age at which the condition is diagnosed. There is usually a progressively greater impact on health from the second decade onwards, producing significant morbidity and life style restriction. In some cases of severe lung damage, heart-lung transplantation is required and in general patients greatly benefit from early diagnosis and management.

Primary ciliary dyskinesia is a phenotypically heterogeneous condition associated with a variety of ultrastructural abnormalities of the cilia and sperm flagella. These include absent dynein arms (approximately 70–80% of cases), absent radial spokes (5–10%), absent central pair microtubules, other rarer microtubular defects, and random ciliary orientation. Genetic linkage analysis and mutational studies in patients with primary ciliary dyskinesia have shown that this disease is genetically heterogeneous, even within groups of families with the same specific ultrastructural defect. An unusual probable dominant inheritance pattern has also been reported for the disease. Mutations in genes encoding two different axonemal outer dynein arm components (DNAI1 and DNAH5) have been shown to cause primary ciliary dyskinesia in a number of patients with outer dynein arm defects. Defects in another dynein, DNAH11, have been

Key points

- Primary ciliary dyskinesia is an autosomal recessive disorder characterised by recurrent sinopulmonary infections, bronchiectasis, and subfertility, due to dysfunction of the cilia. Fifty percent of patients with primary ciliary dyskinesia have defects of laterality (situs inversus) and this association is known as Kartagener syndrome. Primary ciliary dyskinesia has an estimated incidence of 1 in 20 000 live births.
- To identify loci for this genetically heterogeneous condition, genome wide linkage scans and subsequent fine mapping were performed in two different isolated populations with distinct ciliary ultrastructural defects, from the Faroe Islands and the Druze community in northern Israel.
- A locus was mapped in seven families from the Faroe Islands to a 2.8 cM interval on chromosome 16p12.1-12.2, with a maximum lod score of 3.15, obtained using GENEHUNTER. A locus was mapped in three out of four Druze families from the Galor region of Israel to a 17 cM region on chromosome 15q13.1-15.1, with a maximum lod score of 3.2 at α (proportion of linked families) = 0.7, using GENEHUNTER.
- This study provides further evidence of the genetic heterogeneity underlying primary ciliary dyskinesia and has established a framework to facilitate isolation of two genes for primary ciliary dyskinesia. Determining the molecular basis of primary ciliary dyskinesia will provide insight into the genetic control of cilia assembly and function and the pathway which determines the vertebrate left right axis.

Abbreviation: PCD, primary ciliary dyskinesia
found in a patient with Kartagener syndrome and normal cilia ultrastructure. The exact role of DNAH11 in primary ciliary dyskinesia has yet to be elucidated. Two other genes for primary ciliary dyskinesia have been localised: CIL2 to 19q.23 and another locus to 15q24 (M P Witt, personal communication).

To identify loci for PCD, genome wide linkage scans and subsequent fine mapping were performed in two different isolated populations with distinct ciliary ultrastructural defects, from the Faroe Islands and the Druze community in northern Israel.

The Faroes comprise a small group of islands in the North Atlantic Ocean located near Iceland, Scotland, and Norway with a relatively young population of mixed Norwegian, Danish, and British ancestry. The islands were colonised at the same time as Iceland, around 1100 years ago and the population size remained small until rapid expansion in the 1800s. The current population size is estimated at 48 000 and has arisen predominantly by indigenous expansion.30 31 The Druze community, a small middle eastern religious sect, was established slightly later, in the eleventh century AD.32 Members live predominately in defined geographical areas of southern Syria, southern Lebanon, and northern Israel and they remain isolated mainly for religious reasons. Both populations are also isolated for geographical and cultural reasons, in the Faroe Islands associated with limited immigration33 34 and in the Druze with a high level of consanguinity.15

With relatively few founders, a limited population size, and recent expansion, the Faroese and Druze populations are suitable for genetic mapping of a heterogeneous recessive disease. This has been demonstrated in the Faroe Island population, in which enrichment of disease incidence associated with specific gene mutations due to founder effects has been shown for cystic fibrosis and glycogen storage disease II.34 35 Similar findings have been reported for several conditions in the well studied Druze population including cystic fibrosis,36 Krabbe disease37 and mucolipidosis.38 However the Druze population has not always proved to be genetically homogeneous.19

We report here the identification of two new PCD loci in these genetic isolates, located on chromosomes 16p12.1-12.2 and 15q13.1-15.1 in the Faroe Island and Druze population respectively.

SUBJECTS AND METHODS

This study was carried out using the two family sets shown in fig 1. Informed consent was obtained in accordance with protocols approved by the University College London Hospital NHS Trust ethical committee. The diagnosis of affected subjects was made according to established clinical criteria supported by abnormal ciliary motility studies and electron microscopy of brushings or biopsy of nasal mucosa.

The Faroe Island resource consisted of seven families comprising 11 affected and 24 unaffected individuals (fig 1A). Clinical findings for some of the patients have been described previously. Only the affected child in UCL140 exhibited situs inversus. Electron microscopy defined an ultrastructural phenotype of absent outer dynein arms in Faroe patients (fig 2B). The patients were Faroese in origin, living on three of the islands only, except for the father in family UCL140, who was from Denmark. The families were treated as unrelated pedigrees in linkage analysis. There was unsupported verbal evidence for distant relatedness between families UCL196, UCL197, and UCL109, however no formal genealogical analysis has been possible to establish the precise relationships. There was one affected parent, the mother in family UCL198.

Four Druze Israeli families were studied comprising 7 affected and 22 unaffected individuals (Three are shown in fig 1B). The parents in three families, UCL122, UCL124, and UCL125, were first cousins, while the fourth family, UCL123, was non-consanguineous. In contrast to the Faroe Island population, Druze patients showed an unusually high incidence of situs inversus (six out of seven affected children). Electron microscopy defined an ultrastructural phenotype of partial absence of the inner dynein arms (fig 2C). Nasal brushings were processed for ultrastructural studies using established techniques and over 100 suitably oriented cross sections of cilia throughout the section were examined to confirm this structural defect. The four families were located in two neighbouring Druze villages comprising 7500 inhabitants, in the mountainous region of the Golan Heights. Families UCL122 and UCL124 were from one village and families UCL123 and UCL125 were from the other.

All of the patients with primary ciliary dyskinesia who were recognised within the two populations were ascertained and there is considerable population enrichment for primary ciliary dyskinesia in both the Faroe Island and Druze populations. The prevalence of primary ciliary dyskinesia in the Faroe Islands is around 1:4500 whilst the local prevalence amongst the Druze population studied is as high as 1:1000.

Genome wide scans of 10 cM density were performed in these two populations using four of the Faroe Island pedigrees (UCL96, 97, 98, and 109) and all four Druze pedigrees (UCL122, 123, 124, and 125). Genomic DNA was extracted from white blood cells using standard methodology. Over 350 hundred microsatellite markers from the Genethon map were genotyped in each family by polymerase chain reaction and fluorescent based semi-automated methodology using methods previously described. Alleles were assigned using Genescan and Genotyper software. Linkage analysis was performed under the assumption of autosomal recessive inheritance with a penetrance of 0.9, a disease allele frequency of 0.007 with equal allele frequencies (0.1) for each marker and a phenocopy rate of 0.00001. This disease allele frequency reflects the worldwide incidence of primary ciliary dyskinesia of 1:20 000. Analysis was also performed using the disease allele frequencies that reflected more closely the actual population frequencies we have determined for each population as described above: 0.015 for the Faroe Island families (incidence 1:4500) and 0.03 for the Druze families (incidence 1:1000). Multipoint analyses were performed using the GENEHUNTER program.

For subsequent fine mapping, six novel microsatellites were determined in the laboratory from the genomic sequence of BAC clones spanning the selected region. The primer pairs used to amplify these polymorphisms were:

- TGTTTCTAGA-GTGTCAGC-3’/5’-ACTGTACCTTCAA CG-3’ (16/1425)
- TGCAACAGACTAGACC-3’/5’-GGTTTCAAATCTCTGAGTC-3’ (16/10321)
- CACGCTGGCTAGAATAG-3’/5’-CTTTACCAGTGACATAC-3’ (15/14)
- GCCTGTATGGA-3’/5’-AAGATTGTCATCTTCCGGTC-3’ (15/20)
- TCTCAGCA-3’/5’-GGTGCCCCTAATC-3’ (15/23)
- GATACCACCTAACAGG-3’/5’-TCACGACAGTGT- TCAGA-3’ (15/36)

Haplotypes were manually constructed using the most parsimonious allele configuration to minimise recombinations. Génèthon marker order and genetic distances were determined from the deCODE Genetics high resolution genetic map. Additional markers were positioned in the deCODE framework map based on their relative position within the human genome sequence available from the U.S. Genome Browser, April 2003 Build 33 sequence freeze.
Pedigrees consistent with linkage on chromosome 16p12.1-12.2 and 15q13.1-15.1. (A) Faroe Island and (B) Druze Israeli haplotypes. Filled symbols indicate individuals affected with primary ciliary dyskinesia, asterisks indicate patients with situs inversus, and a double line indicates first cousin marriage. Genetic markers used in the initial genome scan are shown in bold and the box indicates the minimum critical interval encompassing each locus. For each marker, alleles are coded numerically such that the same allele number correlates to the same allele size across families. The frameworks of microsatellite markers used were as follows with genetic distances indicated in Kosambi cM:

- D16S3046, 2.59
- D16S3076, 0.003
- D16S403, 0.1
- D16S412, 0.5
- D16S417, 1.3
- D16S401, 0.01
- D16S3133, 0.31
- D16S3093, 1.55
- D15S975, 2.09
- D15S1002, 6.02
- D15S1048, 1.57
- D15S165, 1.99
- D15S1031, 0.22
- D15S118, 4.02
- D15S971, 0.27
- D15/14, 1.38
- D15/20, 0.87
- D15/1007, 1.09
- D15/2004, 0.96
- D15/23, 0.92
- D15/232, 0.88
- D15/36, 2.75
- D15/12, 1.12
- D15/18, 4.02
- D15/1012. Genetic distances were taken from the DeCODE map except for markers 16/4125, 16/10321, D16S3094, 15/14, D15S1010, 15/20, 15/23, D15S122, and 15/36. These were positioned relative to the DeCODE marker framework using Human Genome Project draft sequence information as described in the text.

Figure 1 Pedigrees consistent with linkage on chromosome 16p12.1-12.2 and 15q13.1-15.1. (A) Faroe Island and (B) Druze Israeli haplotypes. Filled symbols indicate individuals affected with primary ciliary dyskinesia, asterisks indicate patients with situs inversus, and a double line indicates first cousin marriage. Genetic markers used in the initial genome scan are shown in bold and the box indicates the minimum critical interval encompassing each locus. For each marker, alleles are coded numerically such that the same allele number correlates to the same allele size across families. The frameworks of microsatellite markers used were as follows with genetic distances indicated in Kosambi cM: D16S3046, 2.59; D16S3076, 0.003; D16S403, 0.1; D16S412, 0.5; D16S417, 1.3; UCL420, 0.36; 16/4125, 0.4; 16/10321, 0.16; D16S401, 0.01; D16S3133, 0.31; D16S3094, 0.69; D16S3068, 0.99; D16S3131, 1.55; D16S3093, and D15S975, 2.09; D15S1002, 6.02; D15S1048, 1.57; D15S165, 1.99; D15S1031, 0.22; 15/14, 1.38; D15S1010, 1.19; 15/20, 0.87; D15S144, 0.57; D15S1007, 1.09; D15S1040, 0.96; 15/23, 0.92; D15S122, 0.88; D15S971, 0.27; 15/36, 1.12; D15S118, 4.02; D15S1012. Genetic distances were taken from the DeCODE map except for markers 16/4125, 16/10321, D16S3094, 15/14, D15S1010, 15/20, 15/23, D15S122, and 15/36. These were positioned relative to the DeCODE marker framework using Human Genome Project draft sequence information as described in the text.
Physical distances were taken from this genomic sequence map.

RESULTS
A region consistent with linkage in the four Faroe Island families was identified on chromosome 16p12.1-13.1. No evidence for linkage at any of the known PCD loci was found. Fine mapping was undertaken in the entire seven family resource which included the three additional families UCL135, UCL139, and UCL140. Linkage analysis using GENEHUNTER was performed across a 9 cM region between markers D16S3046 and D16S3093. This gave a maximum multipoint lod score of 3.15 between markers D16S412 and 16/10321. Using a disease allele frequency calculated from the actual recorded Faroe Island population disease incidence rather than worldwide incidence of primary ciliary dyskinesia, the maximum lod score obtained was 3.13. This is probably a conservative estimate of the true degree of linkage as the families were only analysed as unrelated pedigrees. Haplotype analysis indicated the key recombinant events defining the critical region on chromosome 16p12.1-12.2 (fig 1A). A paternal recombination in family UCL98 at D16S403 defined the telomeric limit of the region. The centromeric limit was defined by a maternal recombination event in family UCL98 at D16S313. The D16S403-D16S313 critical interval spans 2.8 cM which corresponds to a physical distance of 2.37 Mb.

Although no statistically significant evidence of a common disease associated haplotype amongst the families could be proven, three markers in the D16S403-D16S313 interval did show a suggestion of linkage disequilibrium with a higher frequency of certain alleles on disease chromosomes compared to control chromosomes. The control data were taken from genotypes on the families’ obligate normal chromosomes and on chromosomes from a small set of unrelated Faroe control individuals. The three markers were 16/4125, D16S401, and D16S313, with p<0.1 for all three using Fisher’s exact test. At 16/4125 allele 2 was present on 3/15 (20%) of disease and 1/25 (4%) of control chromosomes; D16S401 allele 2 was present on 6/15 (40%) of disease and 7/25 (28%) of control chromosomes; and D16S313 allele 1 was present on 8/15 (53%) disease and 3/13 (23%) of control chromosomes. All other markers in the entire D16S3046-D16S3093 interval were non-significant. It was also noted that the affected child in family UCL98 is homozygous for the haplotype 3-2-2 at markers 16/4125-16/10321-D16S401.

Data from one additional Faroe Island pedigree were not included in the present study. Exclusion from the chromosome 16 locus was indicated in this family suggesting the possibility of locus heterogeneity amongst Faroe Islanders. However clinical data on the individual who appears to be recombinant across the region if affected remains incomplete and the affection status of this individual remains uncertain at present.

Three out of four of the Druze families were consanguineous and a homozygosity mapping approach was used. Genome scan markers were scored for homozygosity in the affected individuals in families UCL122, UCL124, UCL125, and for consistency of linkage in the non-consanguineous family UCL123. Four regions of excess homozygosity were identified on chromosomes 1q32, 3p25, 5q33, and 15q13. Fine mapping using additional markers at each region resulted in exclusion of all regions except that on chromosome 15q13. Linkage analysis using GENEHUNTER across a 25 cM region between markers D15S975 and D15S1012 gave a maximum multipoint lod score between markers D15S1031 and D15S118 of 3.2 allowing for heterogeneity, at \( \pi \) (proportion of linked families) = 0.73 which suggested that three out of four families were linked. Using a disease allele frequency calculated from the actual recorded Druze population disease incidence rather than worldwide incidence of primary ciliary dyskinesia, the maximum lod score obtained dropped to 3.0. Haplotype analysis confirmed linkage in families UCL122, UCL123, and UCL125, but not in UCL124. No evidence for linkage of family UCL124 to any of the known PCD loci was found. The key recombination events defining the critical region were determined (fig 1B). The centromeric and telomeric limits of the region were defined by loss of homozygosity at D15S1048 in the affected child in UCL125 and a maternal recombination in family UCL122 at D15S1012 respectively. The D15S1048-D15S1012 critical interval on chromosome 15q13.1-15.1 spans a region of 17 cM, corresponding to a physical distance of 9.1 Mb. Interestingly the non-consanguineous family UCL123 was homozygous by descent for alleles at the markers D15S1031, 15/14, D15S1010, 15/23, and D15S1232, identifying these as regions of potential interest if the families harbour a single ancestral mutation. However the significance is reduced since there was no evidence of allele sharing amongst affected Druze patients.

DISCUSSION
These results provide statistically significant support for loci for primary ciliary dyskinesia on chromosomes 16p12.1-12.2 and 15q13.1-15.1. Since primary ciliary dyskinesia is a genetically and clinically heterogeneous disorder the selection of patients with an identical ultrastructural phenotype and families from isolated populations should minimise the risk of genetic heterogeneity. The incidence of inbreeding is often high in these populations which may allow the application of homozygosity or linkage disequilibrium mapping to identify and refine the disease gene localisation. This is a powerful approach and has proved successful in mapping many autosomal recessive diseases including...
primary ciliary dyskinesia, even in the presence of heterogeneity.\textsuperscript{24, 47–48} This study uses PCD family groups from two genetically isolated populations from the Faroe Islands and the Golan Heights Druze community, both of which were founded and have expanded relatively recently. There is significant enrichment for primary ciliary dyskinesia in both these populations presumably due to isolation and inbreeding, the incidence being around 1:4500 in the Faroe Islands and 1:1000 in the Druze population studied.

In both populations the initial assumption was that the existence of single ancestral Faroe Island or Druze mutation would account for all the patients in each group. However, in the present study such linkage disequilibrium has not been detected. At the Faroeos locus no common haplotype was observed among the affected subjects even amongst families UCL96, UCL97, and UCL109, who may be interrelated, and the allele sharing observed was not statistically significant. Identification of linkage disequilibrium by additional marker typing at both loci would be useful to further refine the critical interval and pinpoint the localisation of the disease gene.

The extent of linkage disequilibrium encompassing a disease gene allele is dependent on course on a number of factors including natural selection and physical features such as the local recombination and gene conversion rate. Population scale effects include the population size, demographic and admixture history. A large population under mutation drift equilibrium displays low levels of linkage disequilibrium while high linkage disequilibrium correlates with a small population due to genetic drift. If the population is reduced, then allelic diversity is lowered and genetic drift is increased. Simulation studies on human populations predicts that slow early growth, such as that which occurred in the Faroe population, can be a key factor in increasing the extent of linkage disequilibrium in an isolated population.\textsuperscript{49, 50} The age of the disease and marker alleles can be regarded as one of the most important considerations; the exact timing of the primary ciliary dyskinesia gene mutation in terms of when it occurred within the population will influence the extent to which it has expanded in the population. If the ancestral mutation is very ancient the region of linkage disequilibrium may have been eroded by ancient recombinations leaving it extremely small.

We have demonstrated locus heterogeneity in the PCD Druze families since only three of the four families are linked to the 15q locus. Moreover the lack of allele sharing suggests allelic heterogeneity. The intense inbreeding within this community could allow different mutations on different haplotypes of a disease gene to expand within the population giving rise to allelic heterogeneity. It has been suggested that multiple mutations in a single specific gene in a small geographic area and in inbred families may in fact be a common phenomenon.\textsuperscript{51, 52} Such allelic heterogeneity has been well described in previous molecular genetic studies in the Druze population. Three different iduronidase mutations were found to cause Hurler syndrome in Druze patients from the Galilee region of Israel\textsuperscript{53} and five different mutations in the arylsulfatase A gene causing metachromatic leucodystrophy, occurring on at least three different haplotypes, were reported in the same region.\textsuperscript{54} Two different mutations and three different genotypes were noted in a small Druze kindred with Wilson’s disease.\textsuperscript{55}

Both critical regions on chromosome 16p12.1-12.2 and 15q13.1-15.1 contain no obvious candidate genes based on known or predicted function or association with axonemal function. The disease genes may therefore encode proteins with a novel structural or regulatory role in cilia or flagella, associated with distinct outer (Faroe Island) and inner (Druze) dynein arm functions. From published reports and expressed sequence tag, protein and gene prediction annotation derived from the UCSC Genome Browser, RefSeq, NCBI Map Viewer, Ensembl transcript and human cDNA collections,\textsuperscript{45–56} the chromosome 16p12.1-12.2 critical region contains 15 distinct genes verified with strong experimental support, and three predicted genes. Using the same criteria the chromosome 15q13.1-15.1 critical region contains 25 well supported genes and 15 predicted genes.

With the identification of two new loci for primary ciliary dyskinesia, the two candidate intervals defined on chromosomes 16p12.1-12.2 and 15q13.1-15.1 provide a framework for the isolation of the putative genes causing primary ciliary dyskinesia. The evolutionary conservation of cilia and flagella structure and function and of the genes encoding axonemal proteins has previously been used to facilitate isolation of human PCD genes.\textsuperscript{26, 27} Along with advances in the human genome project there has been huge progress with the genome projects for the flagellated PCD model organisms *Chlamydomonas* and *Trypanosoma*.\textsuperscript{57–59} Their genome sequence information and annotation is publicly available (http://genome.jgi-psf.org/chlre1/chlre1.home.html, http://parsun1. path.cam.ac.uk/overview.htm) and it is now possible to incorporate cross species comparative genomics into the bioinformatics based prioritisation of PCD candidate genes. Technical advances in genetic manipulation of these model organisms are also of great potential value, for example for screening for a flagellar phenotype in mutant *Chlamydomonas* and *Trypanosoma* strains in which the expression of homologues of PCD candidate genes has been ablated by RNA interference.\textsuperscript{60–62}

Another postgenomic approach applied to the study of cilia structure and function is also likely to prove useful in the search candidate genes for primary ciliary dyskinesia. Ostrowski and colleagues recently reported results from the first proteomic analysis of the human ciliary axoneme, aimed at characterising all the constitutive protein components.\textsuperscript{63} In this study one and two dimensional gel electrophoresis of cilia from human bronchial epithelial biopsy produced a map of over 200 putative axonemal proteins, yielding many potentially novel components of this complex organelle. Our own bio-informatic analysis has indicated that none of the available protein sequences from this study correspond to gene products predicted to map to either the 16p12.1-12.2 or the 15q13.1-15.1 loci. Ciliary actin identified in the proteomic set does have domain similarity to both a cardiac specific and a skeletal muscle specific actin isoform located in the critical region on chromosome 15 but there does not appear to be a functional correlation. Proteomic studies such as this have enormous promise and are highly appropriate for analysis of the cilium. Techniques for more direct analysis of complex protein mixtures using methods based on mass spectrometry and the development of protein “chips” are actively evolving fields which will further advance this approach.\textsuperscript{64}

In conclusion, this study reinforces the value of isolated human populations in gene mapping of heterogenous disorders. Determining the molecular basis of primary ciliary dyskinesia will provide insight into the genetic control of cilia assembly and function and the pathway which determines the vertebrate left-right axis.

**ACKNOWLEDGEMENTS**

We are grateful to the populations of the Faroe Islands and Israel Golan Heights and to all the individuals who participated in this study. We thank Drs Michael Dunn, Amanda Walne, Martin Gray and Ms Laure Boudery for clinical ascertainment and technical support. We thank Drs Christopher O’Callaghan and Wendy Stannard for the electron micrograph of a normal axoneme.

www.jmedgenet.com


Lerend EL, Boitstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. Science 1997;276:1567–70.


References
CORRECTION

doi: 10.1136/jmg.2003.014761corr1

Venturin M, Guarneri P, Natacci P, et al. Mental retardation and cardiovascular malformations in NF1 microdeleleted patients point to candidate genes in 17q11.2. (J Med Genet 2003; 41:35–41). We would like to offer our sincere apologies to the authors of this paper for a number of errors that were introduced regarding the incorrect use of the term “learning disability”. The instances of “learning disability” in the Key points box, and in Tables 1 and 2 should be “mental retardation”. These errors are much regretted and the corrected versions are shown here.

Table 1 Presence of specific clinical signs in 92 NF1 microdeleleted patients v NF1 patients according to published reports

<table>
<thead>
<tr>
<th>Clinical signs</th>
<th>NF1 microdeleated patients</th>
<th>NF1 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total evaluable</td>
<td>Total affected</td>
</tr>
<tr>
<td>Plexiform neurofibroma</td>
<td>88</td>
<td>25</td>
</tr>
<tr>
<td>Macrocephaly</td>
<td>63</td>
<td>20</td>
</tr>
<tr>
<td>Facial dysmorphism</td>
<td>88</td>
<td>69</td>
</tr>
<tr>
<td>Hypertelorism</td>
<td>64</td>
<td>27</td>
</tr>
<tr>
<td>Mental retardation</td>
<td>63</td>
<td>36</td>
</tr>
<tr>
<td>Seizures</td>
<td>56</td>
<td>5</td>
</tr>
<tr>
<td>Cardiovascular malformations</td>
<td>61</td>
<td>11</td>
</tr>
<tr>
<td>Deafness</td>
<td>82</td>
<td>2</td>
</tr>
<tr>
<td>Scoliosis</td>
<td>60</td>
<td>9</td>
</tr>
<tr>
<td>Pectus excavatum-carinatum</td>
<td>58</td>
<td>10</td>
</tr>
</tbody>
</table>

*The discordant values between the two groups of patients and the relative clinical signs are given in bold. Including the following signs, each observed in at least one patient: coarse face, flat occiput/brachycephaly, facial asymmetry, prominent forehead, frontal bossing, ptosis, downsloping deep set eyes, elevation of the lateral eyelid, epicanthic folds, strabismus, large nose, prominent nose, high nasal bridge, broad nasal bridge, broad nose, bulbous nasal tip, large ears, low set ears, malar hypoplasia, wide philtrum, prominent philtrum, small mouth, thick lips, micrognathia, small pointed chin, low posterior hairline.

*Including: atrial septal defect, ventricular septal defect, patent ductus arteriosus, pulmonary stenosis, dilated aortic valve, hypertrophic cardiomyopathy, mitral valve prolapse.
Table 2 Clinical features of the 14 newly described patients carrying NF1 microdeletion characterised by refined fluorescent in situ hybridisation (FISH) analysis

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Deletion type</th>
<th>Clinical signs</th>
<th>Growth defects</th>
<th>Dysmorphic</th>
<th>Mental retardation</th>
<th>Cardiovascular malformation</th>
<th>Other features</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>4</td>
<td>M</td>
<td>REP</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>Optic glioma, seizures</td>
</tr>
<tr>
<td>118</td>
<td>5</td>
<td>M</td>
<td>cen-REP</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>Broad neck, 3 NFs</td>
</tr>
<tr>
<td>93</td>
<td>6</td>
<td>M</td>
<td>REP</td>
<td>Height 3rd centile, microcephaly 2nd centile</td>
<td>Yes†</td>
<td>IQ48</td>
<td>VSD (upper part)</td>
<td>–</td>
<td>Small hands/feet, short fingers</td>
</tr>
<tr>
<td>116</td>
<td>6</td>
<td>M</td>
<td>REP</td>
<td>Short stature 10th centile</td>
<td>Yes‡</td>
<td>IQ54</td>
<td>Mitral insufficiency</td>
<td>–</td>
<td>MCLS, kyphoscoliosis, pectus excavatum, genu valgus, pes planus, umbilical hernia</td>
</tr>
<tr>
<td>72</td>
<td>7</td>
<td>M</td>
<td>REP</td>
<td>No</td>
<td>Yes§</td>
<td>IQ30</td>
<td>–</td>
<td>–</td>
<td>Small hands/feet, short fingers</td>
</tr>
<tr>
<td>76</td>
<td>8</td>
<td>F</td>
<td>REP</td>
<td>No</td>
<td>Yes*</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>94</td>
<td>8</td>
<td>F</td>
<td>REP</td>
<td>No</td>
<td>Yes**</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>76</td>
<td>8</td>
<td>F</td>
<td>REP</td>
<td>No</td>
<td>Yes††</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>77</td>
<td>11</td>
<td>M</td>
<td>REP</td>
<td>Overgrowth &gt;97th centile</td>
<td>Yes††</td>
<td>Speech</td>
<td>–</td>
<td>–</td>
<td>MCLS, amblyopia, thalamic hamartoma</td>
</tr>
<tr>
<td>82</td>
<td>23</td>
<td>F</td>
<td>REP</td>
<td>Short stature</td>
<td>No</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Hearing impairment, Noonan-like</td>
</tr>
<tr>
<td>77</td>
<td>U</td>
<td>F</td>
<td>REP</td>
<td>Overgrowth &gt;97th centile</td>
<td>Yes††</td>
<td>Speech</td>
<td>–</td>
<td>–</td>
<td>NFs, required special education, short and broad fingers and toes</td>
</tr>
<tr>
<td>78</td>
<td>U</td>
<td>F</td>
<td>REP</td>
<td>–</td>
<td>Yes**</td>
<td>Speech</td>
<td>–</td>
<td>–</td>
<td>Delayed motor development, short and broad feet, fifth finger clinodactyly</td>
</tr>
</tbody>
</table>

*Hypertelorism, epicanthic folds, low set ears, low posterior hairline.
†Hypertelorism, downslanting eye, strabismus, large and prominent nose with high and broad bridge, bulbous nasal tip, large and low set ears, malar hypoplasia, wide and prominent philtrum, small mouth, small pointed chin.
‡Hypertelorism, long philtrum, broad nose.
§Prominent forehead, hypertelorism, ptosis (O.DX), downslanting eyes; strabismus, large and prominent nose with high and broad bridge and bulbous nasal tip, large and low set ears, wide and prominent philtrum, low posterior hairline.
*Coarse face, hypertelorism.
**Epicanthic folds, bulbous nose, narrow high palate, low forehead.
††Epicanthic folds, bulbous nose, low set ears, low posterior hairline.
‡‡Epicanthic folds, bulbous nose, narrow high palate, low forehead.
§§Simple facial features.
***Epicanthic folds, bulbous nose, narrow high palate, low forehead.
### Key points

- **NF1 microdeletion syndrome** is determined by haplo-insufficiency of the NF1 gene and its flanking regions; NF1 microdeleted patients show a more severe phenotype than observed in classical NF1 patients.
- The aim of this study was to verify the presence of specific clinical signs of NF1 microdeletion, by combining clinical and genetic evidence from 92 deleted patients, 14 newly characterised and 78 already published.
- Statistical analysis, done by comparing the frequency of 10 clinical signs between NF1 microdeleted patients and the whole NF1 population, showed that the most common extra-NF1 clinical signs in microdeleted patients were mental retardation, cardiovascular malformations, and dysmorphisms.
- Using bioinformatic tools, the deletion gene content of 44 genetically and clinically characterised patients was established. It is proposed that haploinsufficiency of OMG and/or CDK5R1 genes may be implicated in mental retardation. In relation to cardiovascular malformations, only JJAZ1 and CENTA2 can be considered as plausible candidate genes.
- When present in an NF1 patient, dysmorphisms, cardiac anomalies, and mental retardation are signs indicating NF1 microdeletion.